operating license. The agency afforded an opportunity for hearing in the Notice of Opportunity for Hearing published in the **Federal Register** on June 28, 2010 (75 FR 36717–36721). The NRC received no request for a hearing or petition for leave to intervene following the notice.

The NRC staff prepared a safety evaluation report for the renewal of Facility Operating License No. R-76 and concluded, based on that evaluation, the licensee can continue to operate the facility without endangering the health and safety of the public. The NRC staff also prepared an Environmental Assessment and Finding of No Significant Impact for the renewal of the facility operating license, noticed in the Federal Register on April 19, 2011 (76 FR 2192821931), and concluded that renewal of the facility operating license will not have a significant impact on the quality of the human environment.

Dated at Rockville, Maryland, this 30th day of September, 2011.

For The Nuclear Regulatory Commission. **Patricia A. Silva**,

Acting Chief, Research and Test Reactors Licensing Branch, Division of Policy and Rulemaking, Office of Nuclear Reactor Regulation.

[FR Doc. 2011-26180 Filed 10-7-11; 8:45 am]

BILLING CODE 7590-01-P

# OVERSEAS PRIVATE INVESTMENT CORPORATION

## Sunshine Notice—October 27, 2011 Board of Directors Meeting

**TIME AND DATE:** Thursday, October 27, 2011, 10 a.m. (Open Portion) 10:15 a.m. (Closed Portion).

**PLACE:** Offices of the Corporation, Twelfth Floor Board Room, 1100 New York Avenue, NW., Washington, DC.

**STATUS:** Meeting OPEN to the Public from 10 a.m. to 10:15 a.m. Closed portion will commence at 10:15 a.m. (approx.).

### **MATTERS TO BE CONSIDERED:**

- 1. President's Report
- 2. Tribute—Christopher J. Hanley

# **FURTHER MATTERS TO BE CONSIDERED:** (Closed to the Public 10:15 a.m.)

- 1. Reports
- 2. Revisions to OPIC Bylaws
- 3. Revised Delegation of Authority
- 4. Finance Project—Egypt and South Sudan (upon the opening of OPIC Programs)
- 5. Finance Project—Guatemala
- 6. Finance Project—Peru
- 7. Finance Project—Mexico
- 8. Finance Project—Global

- 9. Finance Project—Mexico, Ukraine, Brazil, Colombia, Jamaica, Egypt, Vietnam, India and Nigeria
- 10. Finance Project—Sierra Leone, Liberia, other West Africa countries
- 11. Finance Project—Sub-Saharan Africa
- 12. Finance Project—Global
- 13. Pending Major Projects

Written summaries of the projects to be presented will be posted on OPIC's Web site on or about October 7, 2011.

### CONTACT PERSON FOR INFORMATION:

Information on the meeting may be obtained from Connie M. Downs at (202) 336–8438.

Dated: October 5, 2011.

### Connie M. Downs,

Corporate Secretary, Overseas Private Investment Corporation.

[FR Doc. 2011–26302 Filed 10–6–11; 4:15 pm]

BILLING CODE 3210-01-P

## OFFICE OF SCIENCE AND TECHNOLOGY POLICY

# Request for Information: Building A 21st Century Bioeconomy

**ACTION:** Notice of Request for Information (RFI).

**SUMMARY:** The purpose of this Request for Information (RFI) is to solicit input from all interested parties regarding recommendations for harnessing biological research innovations to meet national challenges in health, food, energy, and the environment while creating high-wage, high-skill jobs.

The public input provided through this Notice will inform the Office of Science and Technology Policy (OSTP) as it works with Federal agencies and other stakeholders to develop a National Bioeconomy Blueprint.

**DATES:** October 7, 2011—December 6, 2011.

### ADDRESSES:

BIOECONOMY@OSTP.GOV.

### SUPPLEMENTARY INFORMATION:

### Purpose

The purpose of this Request for Information (RFI) is to solicit input from all interested parties regarding recommendations for harnessing biological research innovations to meet national challenges in health, food, energy, and the environment while creating high-wage, high-skill jobs.

The public input provided through this Notice will inform the Office of Science and Technology Policy as it works with Federal agencies and other stakeholders to develop a National Bioeconomy Blueprint.

### **Background**

On September 16, 2011, President Obama announced that his Administration will develop a National Bioeconomy Blueprint detailing Administration-wide steps to harness biological research innovations to address national challenges in health, food, energy, and the environment. Biological research underpins the foundation of a significant portion of our economy. By better leveraging our national investments in biological research and development, the Administration will grow the jobs of the future and improve the lives of all Americans.

Twenty-first century advances in biological research and technologies are poised to return tremendous public benefits. For example, advances in human genome-informed personalized medicine and data analytics could be combined to improve human health in novel ways. In bio-based industry, biological design can create new opportunities for biofuels, chemicals, materials, and energy-efficient manufacturing processes.

The National Bioeconomy Blueprint will identify strategies to meet grand challenges, promote commercialization and entrepreneurship, focus research and development investments in areas that will provide the foundation for the bioeconomy, expand workforce training to prepare the next generation of scientists and engineers for the bioeconomy jobs of the future, identify regulatory reforms that will reduce unnecessary burdens on innovators while protecting health and safety, and describe appropriate public-private partnerships to accelerate innovation in key areas.

OSTP seeks comment on the questions listed below to inform the development of the National Bioeconomy Blueprint:

Grand challenges: President Obama has identified "grand challenges" as an important element of his innovation strategy, such as "smart anti-cancer therapeutics that kill cancer cells and leave their normal neighbors untouched; early detection of dozens of diseases from a saliva sample; personalized medicine that enables the prescription of the right dose of the right drug for the right person; a universal vaccine for influenza that will protect against all future strains; and regenerative medicine that can end the agonizing wait for an organ transplant."

(1) Identify one or more grand challenges for the bioeconomy in areas such as health, energy, the environment, and agriculture, and suggest concrete